107
Participants
Start Date
July 11, 2013
Primary Completion Date
October 8, 2020
Study Completion Date
December 3, 2020
Milademetan
DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
Milademetan
Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
Columbia University College of Physicians and Surgeons, New York
Memorial Sloan Kettering Cancer Center, New York
Tennessee Oncology, Nashville
Karmanos Cancer Institute, Detroit
UT MD Anderson Cancer Center, Houston
Lead Sponsor
Daiichi Sankyo
INDUSTRY